Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

NCT02391545 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT02391545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02391545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Lead sponsor
SecuraBio
Phase
Phase 1/2
Overall status
Terminated
Start date
December 31, 2014
Completion date
May 31, 2017
Enrollment
55 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cd20+ follicular lymphoma